Portal de Periódicos da CAPES

RENAL CELL CARCINOMA: MANAGEMENT OF ADVANCED DISEASE

1999; Lippincott Williams & Wilkins; Volume: 161; Issue: 2 Linguagem: Inglês

10.1016/s0022-5347(01)61897-4

1527-3792

Robert A. Figlin,

Bladder and Urothelial Cancer Treatments

No AccessJournal of UrologyClinical Urology: Review Article1 Feb 1999RENAL CELL CARCINOMA: MANAGEMENT OF ADVANCED DISEASE ROBERT A. FIGLIN ROBERT A. FIGLINROBERT A. FIGLIN View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)61897-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We provide a current review of the management of advanced renal cell carcinoma. Materials and Methods: A comprehensive literature review of peer reviewed articles which address the current management of metastatic renal cell carcinoma was performed. Results: Renal cell carcinoma is the seventh leading cause of cancer, accounting for 3% of malignancies in men. The incidence of renal cell carcinoma has increased significantly by 38% from 1974 through 1990 at least in part related to earlier diagnosis with the common use of new radiological techniques. Cytotoxic chemotherapy remains poor as a treatment alternative. Interferon-alpha produces responses in 15 to 20% of patients but clinical usefulness as monotherapy has been surpassed by interleukin-2 (IL-2). IL-2 is the first immunotherapy to produce durable remissions resulting in approval by the Food and Drug Administration. Although high dose bolus IL-2 schedules have the longest followup, IL-2 administered on other schedules may have enhanced efficacy. Randomized trials are attempting to delineate the appropriate role for various doses and schedules. Conclusions: Advanced renal cell carcinoma, once a disease relegated to the incurable, during the last decade has evolved into a malignancy that may be associated with cure. The first evidence of this potential is the clear and unequivocal demonstration that IL-2 produces durable complete remissions. Building upon this immunotherapeutic approach the future treatment of renal cell carcinoma will incorporate new immunological technology, including gene, dendritic cell, vaccine and antibody therapy. References 1 : Cancer statistics, 1998. Cancer J. Clin.1998; 48: 6. Google Scholar 2 : Pathology, biology, and clinical staging of renal cell carcinoma. Sem. Oncol.1989; 16: 3. Google Scholar 3 : Cancer of the kidney and ureter. In: . Philadelphia: J. B. Lippincott1993: 1023. Google Scholar 4 : Bethesda, Maryland: NIH pub. no. 93-2789. National Cancer Institute1993. Google Scholar 5 : Effect of improved diagnosis of renal cell carcinoma on the course of the disease. J. Surg. Oncol.1994; 57: 201. Google Scholar 6 : Prognostic significance of incidental renal cell carcinoma. Eur. Urol.1995; 27: 319. Crossref, Medline, Google Scholar 7 : Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for RCC.. J. Natl. Cancer Inst.1986; 77: 351. Google Scholar 8 : Renal cell carcinoma: basic biology and clinical behavior. Sem. Urol. Oncol.1996; 14: 208. Google Scholar 9 : Renal-cell carcinoma. New Engl. J. Med.1996; 335: 865. Google Scholar 10 : Hereditary renal-cell carcinoma associated with a chromosomal translocation. New Engl. J. Med.1979; 301: 592. Google Scholar 11 : Familial renal cell carcinoma with a 3:11 chromosome translocation limited to tumor cells. Science1982; 217: 939. Google Scholar 12 : Identification of the von Hippel-Lindau (VHL) gene: its role in renal cancer. J.A.M.A.1995; 273: 564. Google Scholar 13 : Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature1988; 332: 268. Google Scholar 14 : Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA1996; 93: 10589. Google Scholar 15 : Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA1996; 93: 10595. Google Scholar 16 : Renal cell carcinoma: recent progress and future directions. Cancer Res.1997; 57: 5189. Google Scholar 17 : Screening for von Hippel-Lindau disease by DNA polymorphism analysis. J.A.M.A.1992; 267: 1226. Google Scholar 18 : Chemotherapy for advanced renal cell carcinoma, 1983–1993. Sem. Oncol.1995; 22: 42. Google Scholar 19 : Phase I trial of vinblastine (VBL) with oral cyclosporine-A (CSA) as a multidrug resistance modifier in renal cell carcinoma (RCC). Proc. Amer. Soc. Clin. Oncol.1992; 11: 204. Google Scholar 20 : A phase I study of infusional vinblastine with the P-glycoprotein antagonist PSC 833 in patients with metastatic cancer. Proc. Amer. Soc. Clin. Oncol.1995; 14: 479. Google Scholar 21 : Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J. Urol.1991; 146: 709. Abstract, Google Scholar 22 : The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J. Urol.1983; 130: 1063. Link, Google Scholar 23 : Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report. J. Clin. Oncol.1985; 3: 1086. Google Scholar 24 : Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. N. Amer.1993; 20: 283. Google Scholar 25 : High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J. Sci. Amer.1997; 3: S70. Google Scholar 26 : Natural history and therapy of metastatic renal cell carcinoma. Cancer1997; 80: 1198. Google Scholar 27 : Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J. Urol.1997; 158: 740. Link, Google Scholar 28 : Renal cell carcinoma and interleukin-2: what are the endpoints?. Cancer J. Sci. Amer.1997; 3: S67. Google Scholar 29 : Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Group Francais d'Immunotherapie. New Engl. J. Med.1998; 338: 1272. Google Scholar 30 : An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J. Sci. Amer.1997; 3: S79. Google Scholar 31 : Interleukin-2 based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J. Sci. Amer.1997; 3: S92. Google Scholar 32 : The natural history of metastatic renal cell carcinoma: a computer analysis. J. Urol.1978; 120: 148. Link, Google Scholar 33 : The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol.1977; 117: 272. Link, Google Scholar 34 : Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Sem. Urol. Oncol.1996; 14: 230. Google Scholar 35 : Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res.1990; 50: 7820. Google Scholar 36 : Interleukin-2 gene transfer into tumor cells abrogates tumorigenecity and induces protective immunity. J. Exp. Med.1990; 172: 1217. Google Scholar 37 : Treatment of established renal cell cancer by tumor cells engineered to secrete interleukin-4. Science1991; 254: 713. Google Scholar 38 : Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J. Clin. Oncol.1993; 11: 738. Crossref, Medline, Google Scholar 39 : Development and characterization of anti-renal cell carcinoma × anti-chelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Cancer Res.1995; 55: 5864S. Google Scholar 40 : Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol.1997; 15: 1529. Google Scholar 41 : Biologic characterization of dendritic cells isolated from patients with advanced renal cell carcinoma (RCC) for potential use in adoptive immunotherapy. Proc. Amer. Soc. Clin. Oncol.1997; 16: 442A. Google Scholar 42 : Specific anti-tumor response against human renal cell carcinoma by dendritic cells loaded with tumor antigens. Proc. Amer. Assn. Cancer Res.1997; 38: 345. Google Scholar From the Division of Hematology-Oncology, UCLA School of Medicine and Solid Tumor Oncology Program, Jonsson Comprehensive Cancer Center, Los Angeles, California(FIGLIN) Financial interest and/or other relationship with Schering, Chiron and the National Kidney Cancer Association.© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byMorrissey J and Kharasch E (2012) The Specificity of Urinary Aquaporin 1 and Perilipin 2 to Screen for Renal Cell CarcinomaJournal of Urology, VOL. 189, NO. 5, (1913-1920), Online publication date: 1-May-2013.Pichler M, Hutterer G, Chromecki T, Jesche J, Kampel-Kettner K, Rehak P, Pummer K and Zigeuner R (2011) External Validation of the Leibovich Prognosis Score for Nonmetastatic Clear Cell Renal Cell Carcinoma at a Single European Center Applying Routine PathologyJournal of Urology, VOL. 186, NO. 5, (1773-1778), Online publication date: 1-Nov-2011.Sanjmyatav J, Junker K, Matthes S, Muehr M, Sava D, Sternal M, Wessendorf S, Kreuz M, Gajda M, Wunderlich H and Schwaenen C (2011) Identification of Genomic Alterations Associated With Metastasis and Cancer Specific Survival in Clear Cell Renal Cell CarcinomaJournal of Urology, VOL. 186, NO. 5, (2078-2083), Online publication date: 1-Nov-2011.Sanjmyatav J, Steiner T, Wunderlich H, Diegmann J, Gajda M and Junker K (2011) A Specific Gene Expression Signature Characterizes Metastatic Potential in Clear Cell Renal Cell CarcinomaJournal of Urology, VOL. 186, NO. 1, (289-294), Online publication date: 1-Jul-2011.Zafar G, Grimm E, Wei W, Johnson M and Ellerhorst J (2009) Genetic Deficiency of Complement Isoforms C4A or C4B Predicts Improved Survival of Metastatic Renal Cell CarcinomaJournal of Urology, VOL. 181, NO. 3, (1028-1034), Online publication date: 1-Mar-2009.Seligson D, Rajasekaran S, Yu H, Liu X, Eeva M, Tze S, Ball W, Horvath S, deKernion J and Rajasekaran A (2007) Na,K-Adenosine Triphosphatase α1-Subunit Predicts Survival of Renal Clear Cell CarcinomaJournal of Urology, VOL. 179, NO. 1, (338-345), Online publication date: 1-Jan-2008.Klatte T, Pantuck A, Riggs S, Kleid M, Shuch B, Zomorodian N, Kabbinavar F and Belldegrun A (2007) Prognostic Factors for Renal Cell Carcinoma With Tumor Thrombus ExtensionJournal of Urology, VOL. 178, NO. 4, (1189-1195), Online publication date: 1-Oct-2007.STEPHENSON A, CHETNER M, ROURKE K, GLEAVE M, SIGNAEVSKY M, PALMER B, KUAN J, BROCK G and TANGUAY S (2018) GUIDELINES FOR THE SURVEILLANCE OF LOCALIZED RENAL CELL CARCINOMA BASED ON THE PATTERNS OF RELAPSE AFTER NEPHRECTOMYJournal of Urology, VOL. 172, NO. 1, (58-62), Online publication date: 1-Jul-2004.ATKINS D, FERRONE S, SCHMAHL G, STÖRKEL S and SELIGER B (2018) Down-Regulation of HLA Class I Antigen Processing Molecules: An Immune Escape Mechanism of Renal Cell Carcinoma?Journal of Urology, VOL. 171, NO. 2, (885-889), Online publication date: 1-Feb-2004.PANTUCK A, ZISMAN A and BELLDEGRUN A (2018) THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMAJournal of Urology, VOL. 166, NO. 5, (1611-1623), Online publication date: 1-Nov-2001.GROSSKLAUS D, HOLZBEIERLEIN J, ROTH B and SMITH J (2018) ABNORMAL MAMMOGRAM AS THE PRESENTING SIGN OF RENAL CELL CARCINOMAJournal of Urology, VOL. 163, NO. 4, (1239-1240), Online publication date: 1-Apr-2000.BLACK P, FILIPAS D, FICHTNER J, HOHENFELLNER R and THÜROFF J (2018) NEPHRON SPARING SURGERY FOR CENTRAL RENAL TUMORS: EXPERIENCE WITH 33 CASESJournal of Urology, VOL. 163, NO. 3, (737-743), Online publication date: 1-Mar-2000. Volume 161Issue 2February 1999Page: 381-387 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.Metrics Author Information ROBERT A. FIGLIN More articles by this author Expand All Advertisement PDF downloadLoading ...